InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,600.80
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.35
(
0.26%
)
Bitcoin
63,471.41
(
-0.82%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

crudeoil24

Send PM Follow Ignore
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

crudeoil24

Member Level

Re: Mark post# 88486

Thursday, 09/03/2015 7:02:07 AM

Thursday, September 03, 2015 7:02:07 AM

Post# of 97237
Geron (NASDAQ:GERN) +20.4% PM on news that the New England Journal of Medicine would publish two papers showing positive results for GERN's flagship drug imetelstat, an inhibitor of the telomerase cancer cell enzyme.In two mid-stage clinical trials, GERN said the use of imetelstat suggested it works against malignant cells that cause essential thrombocythemia, a disease in which the body produces too many blood platelets, and against myelofibrosis, a bone marrow disease that disrupts the body's production of blood cells.

DUKE BASKETBALL and NOTRE DAME FOOTBALL

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up